The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic
For several years we have known that biologics for psoriasis are associated with an increased risk of infection – but what is the risk of respiratory tract infections and serious infections, like COVID-19? In this MEDtalk, Lara Van Der Schoot and Juul van den Reek, Radboud Institute for Health Sciences and Department of Dermatology, The Netherlands, discuss the risk of COVID-19, and whether there is a differential risk of infections between the biologics targeting different interleukins.
Få adgang til artiklen
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.